TC
CPIX icon

TFS Capital’s Cumberland Pharmaceuticals CPIX Stock Holding History

TFS Capital’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-20,896
Closed -$146K – 76
2017
Q2 		$146K Buy
20,896
+9,397
+82% +$62K 0.06% 503
2017
Q1 		$80K Buy
+11,499
New +$69.7K 0.03% 607

Other funds holding CPIX

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TFS Capital's CPIX Position: Q3 2017 in Review

TFS Capital sold out of Cumberland Pharmaceuticals (CPIX) in Q3 2017, closing a stake of 20,896 shares — an estimated $146K sold.

TFS Capital first reported a position in CPIX in Q1 2017 and held it in 2 quarters. The position peaked at $146K in Q2 2017. 33 funds tracked by Wall St. Rank hold CPIX as of Q3 2017.

  • TFS Capital reported no remaining Cumberland Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 20,896 Cumberland Pharmaceuticals shares in Q3 2017, an estimated $146K.
  • TFS Capital first reported a position in Cumberland Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • TFS Capital's Cumberland Pharmaceuticals position peaked at $146K in Q2 2017.
  • 33 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.